Navigation Links
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
Date:6/1/2009

tiple myeloma: Preliminary results" (Abstract #8541).

About Multiple Myeloma

According to the American Cancer Society, in 2009, approximately 20,500 new cases of multiple myeloma will be diagnosed in the United States. Newly diagnosed patients have treatment options that include combination chemotherapeutic agents and stem cell transplantation. While many patients respond to treatment, most eventually relapse and require subsequent treatment. Few patients are ultimately cured of their disease. In spite of advances in the treatment of multiple myeloma, this year alone, approximately 10,500 patients are expected to die of the disease.

About Carfilzomib

Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's macroglobulinemia, mantle cell lymphoma and renal cell carcinoma.

Proteolix is conducting a comprehensive clinical development program evaluating carfilzomib for the treatment of multiple myeloma, including an ongoing accelerated approval study in heavily pre-treated relapsed/refractory patients and a Phase 2 clinical trial in relapsed patients stratified by prior treatment with bortezomib. Both Phase 2 clinical trials are being conducted by Proteolix in collaboration with the Multiple Myeloma Research Consortium (MMRC). A Phase 1b clinical trial of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma is also ongoing. In addition, Proteolix is conducting a single-agent Phase 2 clinical trial of carfilzomib in patients with recurrent or advanced solid tumors. For the la
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
2. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
4. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
5. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
11. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... - More than fifty years ago, Thalidomide was approved by ... mothers. Tragically, Thalidomide caused serious and permanent physical and emotional ... has been provided to survivors over the years from sources ... in 1991 and settlements from drug companies. ... provide support, we have a clear moral obligation to help ...
(Date:5/22/2015)... 2015 The leading companies in the ... cardiac rhythm management device market dominate their competition, ... St. Jude Medical, Boston Scientific and Asahi Kasei ... segment. The healthcare market research publisher,s report, ... as a base year, providing forecasts for each ...
(Date:5/22/2015)... ROCKVILLE, Md. , May 22, 2015 /PRNewswire/ ... "RegeneRx") today announced a peer-reviewed publication of the ... study evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for ... Inc.,s controlled adverse environment (CAE ® ) model.  ... and the results, which were previously disseminated by ...
Breaking Medicine Technology:Statement from Minister Ambrose on Thalidomide 2Statement from Minister Ambrose on Thalidomide 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... May 18, 2011 Ovid, part of ... the delivery of customizable electronic research information for the medical, scientific, ... OvidMD , the first clinical ... provides quick answers to clinical questions based on relevant full-text content ...
... FRANCISCO, May 18, 2011 Bayer HealthCare Pharmaceuticals, Inc. and ... that data evaluating the use of Nexavar® (sorafenib) tablets will ... Meeting of the American Society of Clinical Oncology (ASCO), June ... committed to researching the potential utility of sorafenib, and the ...
Cached Medicine Technology:Ovid Announces its First Clinical Tool, OvidMD, Designed for Physicians and Other Clinicians 2Ovid Announces its First Clinical Tool, OvidMD, Designed for Physicians and Other Clinicians 3Ovid Announces its First Clinical Tool, OvidMD, Designed for Physicians and Other Clinicians 4Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 2Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 3Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 4Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 5Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 6Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 7
(Date:5/23/2015)... May 23, 2015 Javon Bea ... the Sports Medicine and Rehabilitation Center, 557 N. Washington ... Mondays, June 1-July 20, 5:30-6:30 pm. , The 8-week ... and Laurie Finke, RN, BSN, who will offer training ... on nutrition, running mechanics and show selection and weekly ...
(Date:5/23/2015)... Baltimore, MD (PRWEB) May 23, 2015 Injury ... moratorium that has been passed by the Maryland legislature but ... , “The Maryland General Assembly passed HB 449 ... the Governor has not signed it into law. This bill ... 2017. Evidence is growing that demonstrates the danger of fracking ...
(Date:5/22/2015)... 22, 2015 Pioneer Millworks, the largest ... forefront of designing with reclaimed wood, introducing their latest ... Angeles, California. Their newest offerings, Vat 35, Reclaimed ... and color to America's largest design event. , “Designers, ... each show, anxious to see and feel the variety ...
(Date:5/22/2015)... Mountain Point Medical Center, a campus of Jordan Valley ... May 29, 2015 at 11 a.m., followed by a community ... center, set to officially open on June 1, 2015, is ... , “The opening of Mountain Point Medical Center is an ... said Kent Loosle, CEO of Mountain Point Medical Center. “Mountain ...
(Date:5/22/2015)... York, New York (PRWEB) May 22, 2015 ... http://www.xareltolawsuit2015.com/ ) filed on behalf of individuals who ... due to its use continue to move forward ... Louisiana. According to a Pretrial Order dated May ... the preservation of documents and electronically stored information. ...
Breaking Medicine News(10 mins):Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4
... cholesterol also control hypertension. // ,Researchers at Warwick ... using statins to reduce cholesterol get a bonus benefit from ... on blood pressure levels too. ,The researchers ... in blood pressure. The overall effect of the use of ...
... cases among the inmates of Tihar Jail in the national ... official report// said here Thursday. ,In 2006, 36 ... 12 in 2002, Minister of State for Home Affairs S. ... that regular health screening camps are being organised by the ...
... problem that has been long overlooked, President A.P.J. Abdul Kalam ... mentally ill women// who have no home. ,"While ... for themselves but also for their families, it becomes critical ... at the beginning of a two-day conference "Mental health - ...
... reminder of the penetration of kidney diseases worldwide. According to ... throes of kidney related ailments. ,Reputed nephrologists emphasized, ... detect the disease early. Kidney transplant and dialysis is simply ... ,Uncomplicated urine tests and blood tests can ...
... A new survey confirms that pulmonary/critical care physicians ... actively managing// their patients’ sleep problems. The survey ... Institute (ACCP-SI). It was found that most pulmonary/critical ... patterns of their female patients and are advising ...
... AMA has written to Health Minister, Tony Abbott, urging ... include funding guarantees// and performance benchmarks for medical training ... (AHCA) negotiations. ,The current AHCA expires ... soon. ,AMA President, Dr Mukesh Haikerwal, ...
Cached Medicine News:Health News:Nearly 2,500 Mentally Ill Women in Delhi are Destitute: Abdul Kalam 2Health News:Doctors Not Drowsy When Treating Women’s Sleep Issue 2Health News:Doctors Not Drowsy When Treating Women’s Sleep Issue 3
Super High Density, multi frequency Side Fire "T intraoperative transducer. A wide field of view is this transducers benefit. Change frequencies on the fly for deeper penetration or for superficial n...
This is a 3D transducer for endovaginal imaging in OB/GYN....
Super High Density, 120 degree field of view, straight handle, multi-frequency, convex endovaginal transducer....
Prostate biopsy transducer....
Medicine Products: